Diabetic Ketoacidosis

Diabetic ketoacidosis (DKA) is a severe, life-threatening metabolic complication of diabetes mellitus (DM) characterized by the triad of hyperglycemia, ketonemia/ketonuria, and metabolic acidosis. It occurs when there is an absolute or relative deficiency of insulin, leading to uncontrolled hepatic glucose production and lipolysis, with subsequent accumulation of ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone) in the blood. DKA is a medical emergency that requires immediate recognition and aggressive therapy to correct fluid deficits, electrolyte imbalances, and acid-base disturbances. In veterinary medicine, DKA is most commonly seen in dogs and cats with diabetes mellitus, often as the initial presentation or as a complication of inadequate insulin therapy or concurrent illness. The condition can be classified as mild, moderate, or severe based on the degree of metabolic acidosis and clinical signs. Systemic effects include osmotic diuresis, dehydration, electrolyte depletion (potassium, phosphorus, magnesium), and impaired cellular function due to acidosis. Without prompt treatment, DKA can progress to shock, coma, and death.

The primary cause of DKA is an absolute or relative deficiency of insulin, which can result from several underlying conditions. In dogs, the most common cause is immune-mediated destruction of pancreatic beta cells, leading to type 1 diabetes mellitus. In cats, type 2 diabetes mellitus is more common, often associated with insulin resistance from obesity, pancreatitis, or concurrent endocrinopathies such as hyperadrenocorticism or acromegaly. Precipitating factors that trigger DKA in diabetic patients include: inadequate insulin administration (missed doses, improper storage, incorrect dosing), insulin resistance due to concurrent illness (e.g., infections, inflammation, neoplasia), stress (e.g., surgery, trauma, pregnancy), and drugs that antagonize insulin (e.g., glucocorticoids, progestogens). In some cases, DKA may be the first manifestation of diabetes mellitus, with no prior diagnosis. Specific etiologies include: pancreatitis (common in both dogs and cats), which can cause transient or permanent beta-cell damage; hyperadrenocorticism (Cushing's syndrome) in dogs, leading to insulin resistance; acromegaly in cats due to growth hormone-secreting pituitary tumors; and diestrus in intact female dogs, where progesterone stimulates growth hormone release. Infections, particularly urinary tract infections, pneumonia, and sepsis, are common precipitating factors. Additionally, certain medications such as glucocorticoids, thiazide diuretics, and beta-agonists can exacerbate hyperglycemia and precipitate DKA.

DKA occurs in dogs and cats with diabetes mellitus. The overall incidence of diabetes mellitus in dogs is estimated at 0.2-1.0%, with a higher prevalence in certain breeds such as Samoyeds, Miniature Schnauzers, Poodles, and Bichon Frises. In cats, diabetes mellitus affects approximately 0.5-2% of the population, with Burmese cats being overrepresented. DKA is reported in up to 40% of dogs and 50% of cats at the time of initial diabetes diagnosis. There is no strong sex predilection, but neutered animals may be at higher risk due to hormonal influences. Age of onset is typically middle-aged to older animals (7-10 years in dogs, 8-13 years in cats). Breed predispositions for DKA specifically are not well-documented, but any breed with a high risk of diabetes is also at risk. Geographic variations are minimal, but obesity and sedentary lifestyle are significant risk factors in cats. Seasonality is not a major factor, but stress-related events such as boarding or hospitalization can precipitate DKA. Concurrent diseases such as pancreatitis, hyperadrenocorticism, and urinary tract infections are common in DKA patients and may influence the epidemiology.

The pathophysiology of DKA involves a complex interplay of insulin deficiency, counter-regulatory hormone excess, and metabolic derangements. Insulin deficiency leads to decreased glucose uptake by insulin-sensitive tissues (muscle, adipose, liver) and increased hepatic gluconeogenesis and glycogenolysis, resulting in hyperglycemia. Simultaneously, counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone) are elevated, further stimulating hepatic glucose production and lipolysis. Lipolysis releases free fatty acids (FFAs) into the circulation, which are taken up by the liver and oxidized to acetyl-CoA. When the capacity of the tricarboxylic acid (TCA) cycle is overwhelmed, acetyl-CoA is converted to ketone bodies (acetoacetate, beta-hydroxybutyrate, acetone). Acetoacetate and beta-hydroxybutyrate are strong organic acids, leading to metabolic acidosis. Hyperglycemia exceeds the renal threshold for glucose reabsorption, causing osmotic diuresis, which results in dehydration, electrolyte loss (sodium, potassium, phosphorus, magnesium), and hyperosmolarity. The osmotic diuresis also leads to hypovolemia, reduced renal perfusion, and impaired renal function. Acidosis impairs cellular function, including cardiac contractility and central nervous system function. Electrolyte disturbances, particularly hypokalemia, can cause muscle weakness, ileus, and cardiac arrhythmias. Hypophosphatemia can lead to hemolysis, rhabdomyolysis, and respiratory muscle weakness. The combination of dehydration, acidosis, and electrolyte imbalances can progress to shock, organ failure, and death if untreated.

Predisposing factors for DKA include intrinsic and extrinsic elements. Intrinsic factors include: genetic predisposition to diabetes mellitus (e.g., certain dog breeds, Burmese cats); obesity, which causes insulin resistance; age (middle-aged to older animals); and concurrent endocrinopathies such as hyperadrenocorticism, acromegaly, and hyperthyroidism (in cats). Pancreatitis is a major predisposing factor, as it can damage beta cells and cause insulin resistance. Extrinsic factors include: inadequate insulin therapy (e.g., missed doses, improper storage, incorrect dosage); stress (e.g., hospitalization, surgery, trauma); infections (e.g., urinary tract infections, pneumonia, sepsis); and administration of insulin-antagonistic drugs such as glucocorticoids, progestogens, and thiazide diuretics. Poor glycemic control, lack of routine veterinary care, and owner non-compliance are also significant. In intact female dogs, diestrus is a risk factor due to progesterone-induced growth hormone secretion. Environmental factors such as diet (high carbohydrate, low fiber) and sedentary lifestyle contribute to obesity and insulin resistance.

Clinical signs of DKA can be acute or insidious. Common presenting signs include polyuria, polydipsia, polyphagia, and weight loss (classic signs of diabetes mellitus). As DKA progresses, signs of systemic illness appear: lethargy, depression, anorexia, vomiting, diarrhea, and dehydration. Physical examination findings may include poor body condition, dehydration (decreased skin turgor, dry mucous membranes, prolonged capillary refill time), tachycardia, weak pulses, and hypothermia or fever. Kussmaul respiration (deep, rapid breathing) may be observed due to metabolic acidosis. Abdominal pain may be present, especially if pancreatitis is concurrent. In severe cases, animals may be recumbent, stuporous, or comatose. Cats may have a characteristic 'plantigrade' stance due to diabetic neuropathy. Ocular findings may include cataracts in dogs (due to sorbitol accumulation) and retinal hemorrhages. Dermatological signs may include poor coat quality, alopecia, and seborrhea. Urinary tract infections are common and may cause dysuria or hematuria. In advanced stages, signs of shock (pale mucous membranes, weak femoral pulses, cold extremities) and organ failure (e.g., acute kidney injury, pancreatitis) may be evident.

Differential diagnoses for DKA include other causes of hyperglycemia, ketosis, and metabolic acidosis. Key differentials include: 1) Hyperosmolar hyperglycemic state (HHS) - characterized by severe hyperglycemia (>600 mg/dL) without significant ketosis or acidosis; differentiation is based on blood gas and ketone measurements. 2) Uremic acidosis (chronic kidney disease) - may present with vomiting, dehydration, and metabolic acidosis, but hyperglycemia is absent or mild; renal parameters (creatinine, BUN) are elevated. 3) Lactic acidosis - can occur with sepsis, shock, or hypoxemia; blood lactate levels are elevated, and glucose is typically normal. 4) Starvation ketosis - occurs with prolonged anorexia or fasting; ketonuria may be present, but blood glucose is normal or low. 5) Ethylene glycol toxicity - causes metabolic acidosis with high anion gap, but hyperglycemia is not a feature; calcium oxalate crystals in urine and characteristic renal changes are present. 6) Salicylate toxicity - can cause metabolic acidosis and hyperglycemia, but history of ingestion and other signs (tachypnea, hyperthermia) are present. 7) Pancreatitis - can cause abdominal pain, vomiting, and secondary diabetes, but hyperglycemia may be transient; lipase and pancreatic-specific lipase (cPLI/fPLI) are elevated. 8) Hepatic lipidosis in cats - can cause hyperbilirubinemia, icterus, and hepatic enzyme elevations; ketosis may be present, but hyperglycemia is not typical. 9) Sepsis - can cause hyperglycemia due to stress and insulin resistance, but blood cultures and inflammatory markers (e.g., CRP) are helpful. 10) Drug-induced hyperglycemia (e.g., glucocorticoids) - history of drug administration and resolution upon withdrawal. Definitive diagnosis of DKA requires hyperglycemia, ketonemia/ketonuria, and metabolic acidosis (pH < 7.3, bicarbonate < 15 mmol/L).

The diagnostic algorithm for DKA begins with a thorough history and physical examination. If DKA is suspected, immediate point-of-care testing should include blood glucose, blood ketones (beta-hydroxybutyrate), and urine dipstick for glucose and ketones. A complete blood count (CBC), serum biochemistry profile, and urinalysis should be performed. Blood gas analysis (venous or arterial) is essential to confirm metabolic acidosis and assess severity. Serum electrolyte concentrations (sodium, potassium, chloride, phosphorus, magnesium) should be measured, as imbalances are common. Additional tests may include serum fructosamine to assess long-term glycemic control, pancreatic lipase immunoreactivity (cPLI/fPLI) to rule out pancreatitis, and urine culture to detect urinary tract infections. Imaging (abdominal ultrasound, thoracic radiographs) may be indicated to identify concurrent diseases such as pancreatitis, adrenal tumors, or pneumonia. In cases with atypical presentation, endocrine testing (e.g., ACTH stimulation test for hyperadrenocorticism, IGF-1 for acromegaly) may be warranted. The diagnosis is confirmed by the presence of hyperglycemia (blood glucose > 250 mg/dL), ketonemia (beta-hydroxybutyrate > 2.5 mmol/L) or ketonuria, and metabolic acidosis (pH < 7.3, bicarbonate < 15 mmol/L). Once diagnosed, treatment should be initiated immediately, and further diagnostic workup for underlying causes can be performed after stabilization.

Laboratory findings in DKA are characteristic. Hematology may show hemoconcentration (increased packed cell volume, hemoglobin) due to dehydration, stress leukogram (neutrophilia, lymphopenia, eosinopenia), or leukocytosis with a left shift if infection is present. Serum biochemistry reveals marked hyperglycemia (typically > 250 mg/dL, often > 400 mg/dL), elevated liver enzymes (ALT, AST) due to hepatic lipidosis or pancreatitis, and increased blood urea nitrogen (BUN) and creatinine due to prerenal azotemia or concurrent kidney disease. Electrolyte abnormalities are common: hyponatremia (due to osmotic dilution), hyperkalemia or hypokalemia (total body potassium is depleted despite initial serum levels), hypophosphatemia, hypomagnesemia, and hyperchloremia or hypochloremia depending on the degree of vomiting. Blood gas analysis shows metabolic acidosis with decreased pH (< 7.3), decreased bicarbonate (< 15 mmol/L), and increased anion gap. Ketone bodies are elevated in blood (beta-hydroxybutyrate > 2.5 mmol/L) and urine (acetoacetate). Serum fructosamine is elevated (> 400 µmol/L in dogs, > 350 µmol/L in cats), indicating poor glycemic control over the past 2-3 weeks. Urinalysis reveals glucosuria, ketonuria, and often a low urine specific gravity (< 1.030) due to osmotic diuresis. Urine sediment may show evidence of urinary tract infection (bacteria, white blood cells). Additional biomarkers such as C-reactive protein (CRP) may be elevated if inflammation is present. Pancreatic lipase immunoreactivity (cPLI/fPLI) is often elevated if pancreatitis is concurrent.

Imaging findings in DKA are primarily used to identify concurrent diseases. Thoracic radiographs may reveal evidence of pneumonia (alveolar pattern), cardiomegaly, or pulmonary edema if heart failure is present. Abdominal radiographs may show hepatomegaly, which is common in diabetic patients due to glycogen accumulation or hepatic lipidosis. Abdominal ultrasound is particularly useful to evaluate the pancreas (enlarged, hypoechoic, or hyperechoic with surrounding inflammation in pancreatitis), liver (diffuse hyperechoic in lipidosis), adrenal glands (enlarged in hyperadrenocorticism), and kidneys (changes consistent with chronic kidney disease). In cats, ultrasonography may also detect acromegaly-associated changes such as thickened kidneys and cardiomyopathy. Echocardiography may be indicated if cardiac disease is suspected. Advanced imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) is rarely needed but may be used to evaluate the pituitary gland in cases of acromegaly or to assess for pancreatic masses. Imaging is not diagnostic for DKA itself but is essential for identifying precipitating factors and complications.

Cytology and histopathology are not typically required for the diagnosis of DKA, but they may be useful in specific situations. Fine-needle aspiration (FNA) of the pancreas may be performed if pancreatitis or pancreatic neoplasia is suspected; cytology may show inflammatory cells (neutrophils, macrophages) in pancreatitis or neoplastic cells in tumors. FNA of the liver may be indicated if hepatic lipidosis is suspected; cytology will show hepatocytes with cytoplasmic vacuolization due to fat accumulation. Histopathology is rarely performed antemortem but may be obtained postmortem. In the pancreas, histopathology may reveal loss of beta cells (in type 1 diabetes), amyloid deposition (in cats with type 2 diabetes), or inflammatory infiltrates (in pancreatitis). In the liver, histopathology may show diffuse vacuolar hepatopathy with lipid accumulation. In the kidney, changes consistent with diabetic nephropathy (glomerulosclerosis, tubular basement membrane thickening) may be seen. Special stains such as Masson's trichrome for fibrosis or Oil Red O for lipid may be used. However, in clinical practice, cytology and histopathology are reserved for cases with atypical presentations or when concurrent diseases are suspected.

Treatment of DKA is a medical emergency and involves several key components: fluid therapy, insulin therapy, electrolyte replacement, and correction of acidosis. The goals are to restore circulating volume, correct dehydration, normalize blood glucose and ketone levels, correct electrolyte imbalances, and treat underlying precipitating factors. Fluid therapy is initiated with isotonic crystalloids (e.g., 0.9% sodium chloride) at a rate to correct shock (e.g., 20-30 mL/kg IV over 15-30 minutes in dogs, 10-20 mL/kg in cats) if hypovolemic, followed by maintenance and replacement of deficits over 12-24 hours. Once blood glucose falls below 250 mg/dL, fluids containing dextrose (e.g., 2.5-5% dextrose in 0.45% sodium chloride) are used to prevent hypoglycemia. Insulin therapy is essential; regular crystalline insulin is administered as a continuous rate infusion (CRI) at an initial dose of 0.05-0.1 U/kg/hour in dogs and 0.05-0.1 U/kg/hour in cats, or as intermittent intramuscular injections (0.2 U/kg initially, then 0.1 U/kg every hour). The insulin dose is adjusted based on blood glucose measurements every 1-2 hours, aiming for a gradual decrease in glucose (50-75 mg/dL/hour). When blood glucose reaches 250 mg/dL, dextrose is added to fluids, and insulin infusion is continued until ketosis resolves. Potassium supplementation is critical; if serum potassium is < 3.5 mEq/L, add 40 mEq/L to fluids; if 3.5-5.0 mEq/L, add 20-30 mEq/L; if > 5.0 mEq/L, do not add initially but monitor closely. Phosphorus supplementation may be needed if serum phosphorus < 2.0 mg/dL, at a dose of 0.01-0.03 mmol/kg/hour IV. Magnesium supplementation is indicated if hypomagnesemia is present. Sodium bicarbonate is generally not recommended unless pH < 7.0 or bicarbonate < 10 mEq/L, and then only a small dose (0.5-1 mEq/kg IV over 30-60 minutes) to avoid paradoxical CSF acidosis. Underlying conditions such as infections, pancreatitis, or endocrinopathies must be treated appropriately. Once the patient is stable and eating, transition to subcutaneous insulin (e.g., NPH, glargine, or detemir) is initiated. Nutritional support is important; a high-fiber, complex-carbohydrate diet is recommended for dogs, while a high-protein, low-carbohydrate diet is recommended for cats. In cats, early use of glargine insulin may promote remission.

The prognosis for DKA is guarded to good with prompt and aggressive treatment. Reported mortality rates range from 5-20% in dogs and 5-15% in cats. Factors associated with a poorer prognosis include: severe acidosis (pH < 7.0), hypokalemia, hypophosphatemia, concurrent pancreatitis, sepsis, acute kidney injury, and advanced age. Cats with diabetic remission have a better long-term prognosis. Short-term prognosis is influenced by the response to therapy; if blood glucose and ketone levels normalize within 24-48 hours, the outlook is better. Medium-term prognosis depends on the ability to manage diabetes mellitus with insulin and diet, and the control of concurrent diseases. Long-term prognosis is variable; many animals can live for years with proper management, but complications such as cataracts (in dogs), neuropathy (in cats), and recurrent DKA can occur. Negative prognostic indicators include persistent ketosis, failure to wean off insulin, and development of complications such as thromboembolism. Regular monitoring and owner compliance are crucial for a favorable outcome.

Follow-up care for DKA patients is essential to prevent recurrence and manage diabetes mellitus. After discharge, patients should be re-evaluated within 1-2 weeks to assess glycemic control and adjust insulin dosages. Serial blood glucose curves (every 2-4 hours over 12-24 hours) are recommended to evaluate insulin efficacy. Serum fructosamine should be measured every 2-3 months to assess long-term control. Owners should be educated on home monitoring of blood glucose (using a glucometer) and urine ketones. Regular veterinary visits every 3-6 months are recommended for physical examination, body weight assessment, and laboratory testing (CBC, biochemistry, urinalysis). Concurrent diseases such as pancreatitis, hyperadrenocorticism, or urinary tract infections should be managed appropriately. In cats, monitoring for diabetic remission is important; if remission occurs, insulin may be tapered and discontinued. Owners should be advised to recognize signs of hypoglycemia (weakness, tremors, seizures) and hyperglycemia (polyuria, polydipsia) and to seek immediate veterinary care if DKA is suspected. Long-term management includes maintaining a consistent diet, exercise, and insulin administration schedule. Regular dental care and parasite control are also important.

Pearls: 1) Always measure blood ketones (beta-hydroxybutyrate) in addition to urine ketones, as urine dipsticks may give false negatives. 2) Use a continuous rate infusion of regular insulin for smoother glycemic control. 3) Add dextrose to fluids when blood glucose falls below 250 mg/dL to prevent hypoglycemia while continuing insulin to suppress ketogenesis. 4) Monitor potassium closely; total body potassium is depleted even if serum levels are normal or high. 5) Consider pancreatitis as a common precipitating factor; measure pancreatic lipase immunoreactivity. 6) In cats, early use of glargine insulin may improve remission rates. 7) Use a low-dose insulin protocol to avoid rapid glucose fluctuations. Pitfalls: 1) Do not administer sodium bicarbonate routinely; it can cause paradoxical CSF acidosis and hypokalemia. 2) Do not use long-acting insulin initially; use regular insulin for rapid effect. 3) Avoid rapid fluid boluses in patients with cardiac disease. 4) Do not discontinue insulin when glucose normalizes; continue until ketosis resolves. 5) Do not ignore hypophosphatemia; it can cause hemolysis and respiratory failure. 6) Do not forget to treat underlying infections; they can perpetuate DKA. 7) Do not use urine glucose alone to monitor therapy; it is not reliable for insulin adjustment.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for DKA: 1) Regular insulin (crystalline zinc insulin): For CRI, dilute 1 U/kg in 250 mL of 0.9% NaCl, infuse at 0.05-0.1 U/kg/hour IV; for intermittent IM, initial dose 0.2 U/kg, then 0.1 U/kg every hour. Adjust based on blood glucose. 2) Dextrose: Add to fluids as 2.5-5% solution when blood glucose < 250 mg/dL. 3) Potassium chloride: Add to fluids at 20-40 mEq/L depending on serum potassium; maximum infusion rate 0.5 mEq/kg/hour. 4) Sodium bicarbonate: Only if pH < 7.0 or bicarbonate < 10 mEq/L; dose 0.5-1 mEq/kg IV over 30-60 minutes. 5) Phosphorus: Sodium or potassium phosphate at 0.01-0.03 mmol/kg/hour IV if serum phosphorus < 2.0 mg/dL. 6) Magnesium sulfate: 0.75-1 mEq/kg/day IV if hypomagnesemia. 7) Antibiotics: If infection is suspected, use broad-spectrum antibiotics such as amoxicillin-clavulanate (13.75 mg/kg PO q12h) or enrofloxacin (5-10 mg/kg PO/IV q24h) in dogs; in cats, use amoxicillin-clavulanate (62.5 mg/cat PO q12h) or cefovecin (8 mg/kg SC q14 days). Adjust based on culture and sensitivity. 8) Antiemetics: Maropitant (1 mg/kg SC q24h) or ondansetron (0.5-1 mg/kg IV q12h) for vomiting. 9) Gastroprotectants: Famotidine (0.5-1 mg/kg IV/PO q12h) or omeprazole (0.7-1 mg/kg PO q24h) if gastritis. 10) Nutritional support: If anorexic, consider enteral feeding via nasoesophageal tube or esophagostomy tube; use a balanced diet. All dosages should be adjusted for renal or hepatic impairment, and drug interactions should be considered (e.g., glucocorticoids antagonize insulin).

Evidence-based literature on DKA in veterinary medicine includes several key studies and consensus guidelines. The ACVIM consensus statement on the diagnosis and treatment of diabetes mellitus in dogs and cats (2018) provides recommendations for DKA management, including fluid therapy, insulin protocols, and monitoring. Studies have compared different insulin protocols; a study by Sears et al. (2012) found that CRI of regular insulin resulted in faster resolution of ketosis compared to intermittent IM injections. Another study by Zeugswetter et al. (2010) evaluated the use of glargine insulin in cats with DKA and found it to be safe and effective. Research on electrolyte management, such as a study by Hume et al. (2006), highlighted the importance of potassium and phosphorus supplementation. A retrospective study by Durocher et al. (2008) reported a mortality rate of 10% in dogs with DKA, with pancreatitis being a common complication. In cats, a study by Sieber-Ruckstuhl et al. (2008) found that diabetic remission was more likely in cats treated with glargine. Meta-analyses are limited, but the overall evidence supports early aggressive fluid therapy, low-dose insulin infusion, and careful electrolyte monitoring. The use of bicarbonate is controversial; most experts recommend against routine use. Future research is needed to optimize insulin protocols and identify biomarkers for prognosis.